2.72
price down icon1.81%   -0.05
after-market Dopo l'orario di chiusura: 3.00 0.28 +10.29%
loading

Perché le azioni Aclaris Therapeutics Inc (ACRS) sono in ribasso?

Abbiamo notato un calo di 10.06% nelle azioni di Aclaris Therapeutics Inc (ACRS) durante la sessione di negoziazione di 2024-12-19. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

  • Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
diagnostics_research LH
$228.61
price up icon 0.72%
$161.88
price up icon 2.40%
$136.02
price up icon 1.51%
diagnostics_research WAT
$368.16
price up icon 2.09%
diagnostics_research MTD
$1,230.74
price up icon 2.05%
$412.26
price up icon 0.79%
Capitalizzazione:     |  Volume (24 ore):